Chinese SLE Treatment And Research Group
Chinese SLE Treatment And Research Group
Explore linked clinical trials.13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus | Systemic Lupus Erthematosus | Not yet recruiting | Phase 2 / Phase 3 | 2026-09-11 | NCT07814664 | |
| Treatment Strategy for Patients With RA-ILD | Rheumatoid Arthritis Associated Interstitial Lung Disease | Not yet recruiting | Phase 4 | 2026-09-03 | NCT07643038 | |
| Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 4 | 2026-07-15 | NCT07381465 | |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, autoimmune disease, blood coagulation disease, blood platelet disease, connective tissue disorder, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, systemic lupus erythematosus, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 / Phase 3 | 2026-06-18 | NCT07657793 | |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis | Aortic Arch Syndromes, Skin and Connective Tissue Diseases, Takayasu arteritis, aortic disorder, arteritis, cardiovascular disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Not yet recruiting | Phase 4 | 2026-03-05 | NCT07451665 | |
| Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2025-09-26 | NCT04582136 | |
| Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2025-07-10 | NCT06881290 | |
| The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis | Aortic Arch Syndromes, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Takayasu arteritis, aortic disorder, arteritis, cardiovascular disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Not yet recruiting | Phase 4 | 2025-06-10 | NCT07013838 | |
| Telitacicept for the Treatment of Refractory RA | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Not yet recruiting | Phase 4 | 2025-06-06 | NCT07008196 | |
| Chinese Rheumatism Biobank(CRB) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Not stated | 2025-04-09 | NCT06887517 | |
| Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Not stated | 2023-12-12 | NCT06167174 | |
| Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 4 | 2023-07-28 | NCT05965284 | |
| Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 4 | 2023-07-27 | NCT05962840 |